Phase 1 · Memphis area, TN
Phase 1 clinical trials in Memphis area, TN
14 recruiting studies have a site in the Memphis area. This page includes nearby cities such as Germantown, Collierville, Cordova, Bartlett.
14 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1/Phase 2
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Xencor, Inc.
- Location
- Cordova, TN + 27 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingHealthy volunteersPhase 1
A Safety Study of IVMED-85 Ophthalmic Solution in Healthy Adults
iVeena Delivery Systems, Inc.
- Location
- Memphis, TN
- Eligibility basics
- Ages 18–49
- RecruitingHealthy volunteersPhase 1
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
St. Jude Children's Research Hospital
- Location
- Memphis, TN
- Eligibility basics
- Up to age 21
- RecruitingPhase 1
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
Cullinan Therapeutics Inc.
- Location
- Memphis, TN + 10 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 1
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
Genentech, Inc.
- Location
- Germantown, TN + 11 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
Jazz Pharmaceuticals
- Location
- Memphis, TN + 20 other US sites
- Eligibility basics
- Ages 12–75
- RecruitingPhase 1/Phase 2
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
AbbVie
- Location
- Cordova, TN + 10 other US sites
- Eligibility basics
- Ages 50–90
- RecruitingPhase 1/Phase 2
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
COUR Pharmaceutical Development Company, Inc.
- Location
- Chattanooga, TN + 44 other US sites
- Eligibility basics
- Ages 12–35
- RecruitingPhase 1/Phase 2
ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
Ionis Pharmaceuticals, Inc.
- Location
- Memphis, TN + 4 other US sites
- Eligibility basics
- Ages 2–12
- RecruitingPhase 1
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
Cullinan Therapeutics Inc.
- Location
- Memphis, TN + 5 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and…
AbbVie
- Location
- Memphis, TN + 4 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 1
Study of BHV-1300 in Graves' Disease
Biohaven Therapeutics Ltd.
- Location
- Memphis, TN + 9 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 1/Phase 2
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
AC Immune SA
- Location
- Cordova, TN + 3 other US sites
- Eligibility basics
- Ages 35–85
- RecruitingPhase 1
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Fate Therapeutics
- Location
- Memphis, TN + 15 other US sites
- Eligibility basics
- Ages 12–70
Who these studies look for
Phase 1 studies often have narrow eligibility: specific age and weight ranges, no recent participation in another study, no nicotine, and limits on medications. Some Phase 1 studies recruit patients rather than healthy volunteers, so check each listing.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.